Key Points
- Vivani Medical Director Gregg Williams bought 1,587,301 shares at $1.26 each, totaling nearly $2.0 million, boosting his direct stake by 4.82% to 34.5 million shares.
- The purchase follows two earlier insider buys by Williams in April and March, suggesting a continued pattern of heavy insider buying in Vivani Medical stock.
- The company recently reported quarterly EPS of -$0.08, matching analyst expectations, while the stock was trading around $1.15 with a market cap of about $99 million.
Vivani Medical, Inc. (NASDAQ:VANI - Get Free Report) Director Gregg Williams acquired 1,587,301 shares of the business's stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $1.26 per share, for a total transaction of $1,999,999.26. Following the transaction, the director directly owned 34,531,785 shares in the company, valued at $43,510,049.10. The trade was a 4.82% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Gregg Williams also recently made the following trade(s):
- On Wednesday, April 15th, Gregg Williams purchased 1,587,301 shares of Vivani Medical stock. The shares were purchased at an average cost of $1.26 per share, for a total transaction of $1,999,999.26.
- On Sunday, March 15th, Gregg Williams purchased 1,575,231 shares of Vivani Medical stock. The shares were purchased at an average cost of $1.07 per share, for a total transaction of $1,685,497.17.
Vivani Medical Trading Up 0.9%
VANI opened at $1.15 on Wednesday. Vivani Medical, Inc. has a 12-month low of $0.92 and a 12-month high of $1.92. The business's fifty day simple moving average is $1.18 and its 200-day simple moving average is $1.29. The company has a market capitalization of $99.18 million, a price-to-earnings ratio of -2.87 and a beta of 2.35.
Vivani Medical (NASDAQ:VANI - Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.08). On average, equities research analysts predict that Vivani Medical, Inc. will post -0.3 EPS for the current year.
Analyst Ratings Changes
Separately, HC Wainwright dropped their price target on Vivani Medical from $4.00 to $3.50 and set a "buy" rating on the stock in a research report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Vivani Medical has an average rating of "Hold" and an average price target of $3.50.
View Our Latest Stock Analysis on VANI
Institutional Investors Weigh In On Vivani Medical
A number of hedge funds have recently made changes to their positions in VANI. Citadel Advisors LLC purchased a new stake in shares of Vivani Medical during the 3rd quarter worth $26,000. Susquehanna International Group LLP lifted its stake in shares of Vivani Medical by 100.5% during the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company's stock worth $46,000 after purchasing an additional 16,200 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Vivani Medical during the 4th quarter worth $60,000. Renaissance Technologies LLC lifted its stake in shares of Vivani Medical by 118.4% during the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company's stock worth $121,000 after purchasing an additional 53,127 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Vivani Medical during the 4th quarter worth $174,000. 6.78% of the stock is currently owned by hedge funds and other institutional investors.
About Vivani Medical
(
Get Free Report)
Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.
The company's flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
